StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research report report published on Monday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, Citigroup cut their price target on Cellectis from $24.00 to $16.00 and set a buy rating for the company in a research note on […]
StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a report released on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, Citigroup dropped their target price on Cellectis from $24.00 to $16.00 and set a buy rating for the company in a report on Wednesday, April […]
StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research report sent to investors on Saturday. The firm issued a hold rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the stock. JMP Securities reiterated a market outperform rating and set a $6.00 price objective […]
StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note released on Saturday. The firm issued a hold rating on the biotechnology company’s stock. A number of other equities research analysts have also issued reports on the company. Oppenheimer cut their target price on Cellectis from $16.00 to $13.00 and […]
NEW YORK, June 09, 2023 Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated. | June 9, 2023